<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uz">
	<id>https://ziyosfera.uz/index.php?action=history&amp;feed=atom&amp;title=Genentech</id>
	<title>Genentech - Oʻzgarishlar tarixi</title>
	<link rel="self" type="application/atom+xml" href="https://ziyosfera.uz/index.php?action=history&amp;feed=atom&amp;title=Genentech"/>
	<link rel="alternate" type="text/html" href="https://ziyosfera.uz/index.php?title=Genentech&amp;action=history"/>
	<updated>2026-11-19T19:14:03Z</updated>
	<subtitle>Ziyosferadagi mazkur sahifaning oʻzgarishlar tarixi</subtitle>
	<generator>MediaWiki 1.45.1</generator>
	<entry>
		<id>https://ziyosfera.uz/index.php?title=Genentech&amp;diff=448024&amp;oldid=prev</id>
		<title>Programmer: Oʻzbekcha Vikipediyadan (UzWiki) 100% asl holatida import qilindi.</title>
		<link rel="alternate" type="text/html" href="https://ziyosfera.uz/index.php?title=Genentech&amp;diff=448024&amp;oldid=prev"/>
		<updated>2026-08-10T18:57:06Z</updated>

		<summary type="html">&lt;p&gt;Oʻzbekcha Vikipediyadan (UzWiki) 100% asl holatida import qilindi.&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Yangi sahifa&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{Shirkat bilgiqutisi|name=Genentech, Inc.|type=Xususiy &amp;lt;ref&amp;gt;{{cite web | url=https://fortune.com/best-workplaces-biotechnology-pharmaceuticals/2021/genentech/ | title=Genentech }}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
(Mustaqil shoʻba korxona)|foundation=1976-yil|key_people={{unbulleted list|Alexander Hardy |([[CEO|CEO]])|Ed Harrington|Sandra J. Horning, M.D.|Michael D. Varney|Stephen Williams|Ph.D.|Sean Johnston|[[Severin Schwan]]|(Genentech direktorlar kengashi raisi, CEO Roche Group)|Anna Batt Ph.D.|[[Aviv Regev]]&amp;lt;ref name=&amp;quot;fiercebiotech&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;Press_Regev&amp;quot;/&amp;gt;}}|industry=[[Biotexnologiya]]|products=[[Avastin]], [[Herceptin]], [[Rituxan]], [[Perjeta]], [[Kadcyla]], [[Gazyva]], [[Tarceva]], [[Ocrelizumab|Ocrevus]], [[Polatuzumab vedotin|Polivy]], [[Atezolizumab|Tecentriq]], [[Baloxavir marboxil|Xofluza]], [[Emicizumab|Hemlibra]], [[Venetoclax|Venclexta]], [[Esbriet]], [[Cobimetinib|Cotellic]], [[Alecensa]], [[Zelboraf]], [[Nutropin]], [[Tocilizumab|Actemra]], [[Lucentis]], [[Xolair]], [[Alteplase|Activase]], [[Cathflo Activase]], [[Xeloda]], [[Boniva (drug)|Boniva]], [[TNKase]], [[CellCept]], [[Peginterferon alfa-2a|Pegasys]], [[Pulmozyme]], [[Tamiflu]], [[Valcyte]], [[Anaprox]], [[Cytovene]], [[Naproxen|EC-Naprosyn]], [[Erivedge]], [[Fuzeon]], [[Invirase]], [[Klonopin]], [[Kytril]], [[Naprosyn]], [[Rocephin]], Roferon-A, [[Romazicon]], [[Valium]], [[Xenical]], [[Zenapax]]|num_employees=13 539 (2021-iyul)|revenue={{Increase}} 26.4 mlrd (2020)&amp;lt;ref&amp;gt;{{cite web | url=https://fortune.com/best-workplaces-biotechnology-pharmaceuticals/2021/genentech/ | title=Genentech }}&amp;lt;/ref&amp;gt;|parent=[[Hoffmann-La Roche]]|homepage=[http://www.gene.com/ www.gene.com]}}&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Genentech, Inc.&amp;#039;&amp;#039;&amp;#039;, 2009-yilda Roche kompaniyasining shoʻba korxonasiga aylangan Amerika [[biotexnologiya]] [[Korporatsiya|korporatsiyasi]]. Genentech Research and Early Development Roche tarkibidagi mustaqil markaz sifatida ishlaydi.&amp;lt;ref&amp;gt;{{Veb manbasi|url=http://www.gene.com/about-us|sarlavha=About Us|ish=Gene.com|kirish sanasi=August 22, 2014|arxivurl=https://web.archive.org/web/20140804185741/http://www.gene.com/about-us|arxivsana=August 4, 2014}}&amp;lt;/ref&amp;gt; Tarixan kompaniya dunyodagi birinchi [[biotexnologiya]] kompaniyasi sifatida qabul qilinadi.&amp;lt;ref&amp;gt;{{Cite journal|last=Russo|first1=Eugene|title=Special Report: The birth of biotechnology|url=https://archive.org/details/sim_nature-uk_2003-01-23_421_6921/page/406|journal=Nature|date=January 2003|volume=421|issue=6921|pages=456–457|doi=10.1038/nj6921-456a|pmid=12540923|bibcode=2003Natur.421..456R}}&amp;lt;/ref&amp;gt; 2021-yil iyul holatiga koʻra, Genentech 13 539 kishini ish bilan taʼminlagan.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |title=Working at Genentech |language=en-US |work=Great Place to Work |url=https://www.greatplacetowork.com/certified-company/1000096 |access-date=November 18, 2021}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Tarixi ==&lt;br /&gt;
Kompaniya 1976-yilda venchur kapitalist Robert A. Swanson va biokimyogar Herbert Boyer tomonidan tashkil etilgan.&amp;lt;ref name=&amp;quot;Nature2003_01_23&amp;quot;&amp;gt;{{Cite journal|last=Russo|first1=E.|title=Special Report: The birth of biotechnology|url=https://archive.org/details/sim_nature-uk_2003-01-23_421_6921/page/406|doi=10.1038/nj6921-456a|journal=Nature|volume=421|issue=6921|pages=456–457|year=2003|pmid=12540923|bibcode=2003Natur.421..456R}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;Genentech_CorporateOverview&amp;quot;&amp;gt;{{Veb manbasi|url=http://www.gene.com/gene/about/corporate/index.jsp?hl=en&amp;amp;q=genentech|sarlavha=Corporate Overview|muallif=Genentech|iqtibos=Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start a biotechnology company, Genentech. Although the two confidently assert that it was the first biotech company, others clearly came before, including [[Cetus Corporation]] which was founded in 1971.|arxivurl=https://web.archive.org/web/20120418082422/http://www.gene.com/gene/about/corporate/index.jsp?hl=en&amp;amp;q=genentech|arxivsana=April 18, 2012}}&amp;lt;/ref&amp;gt; Boyer rekombinant DNK texnologiyasi sohasida kashshof hisoblanadi. 1973-yilda Boyer va uning hamkasbi Stanley Norman Cohen cheklovchi fermentlarni xuddi shunday kesilgan plazmid vektoriga bogʻlash uchun bir manbadan [[Dezoksiribonuklein kislota|DNK]] parchalarini kesish uchun „qaychi“ sifatida foydalanish mumkinligini koʻrsatdi.&amp;lt;ref&amp;gt;{{Cite journal|last=Cohen|first1=S.|last2=Chang|first2=A.|last3=Boyer|first3=H.|last4=Helling|first4=R.|title=Construction of biologically functional bacterial plasmids in vitro|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=70|issue=11|pages=3240–3244|year=1973|pmid=4594039|pmc=427208|doi=10.1073/pnas.70.11.3240|bibcode=1973PNAS...70.3240C}}&amp;lt;/ref&amp;gt; Cohen akademiyada laboratoriyaga qaytganida, Swanson kompaniyani ochish uchun Boyer bilan bogʻlandi.&amp;lt;ref name=&amp;quot;Nature2003_01_23&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;&amp;quot;In January 1976, 28-year-old venture capitalist Robert Swanson entered the picture. &amp;lt;/ref&amp;gt; Boyer Bekman ilmiy-tadqiqot institutidan Arthur Riggs va Keiichi Itakura bilan ishlagan va guruh 1977-yilda somatostatin [[Gormonlar|gormonini]] ishlab chiqarganida birinchi boʻlib [[Bakteriyalar|bakteriyalarda]] inson [[Gen|genini]] muvaffaqiyatli ifodalagan.&amp;lt;ref&amp;gt;{{Cite journal|doi=10.1126/science.412251|last=Itakura|first1=K.|last2=Hirose|first2=T.|last3=Crea|first3=R.|last4=Riggs|first4=A. D.|last5=Heyneker|first5=H. L.|last6=Bolivar|first6=F.|last7=Boyer|first7=H. W.|title=Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin|url=https://archive.org/details/sim_science_1977-12-09_198_4321/page/n84|journal=Science|volume=198|issue=4321|pages=1056–1063|year=1977|pmid=412251|bibcode=1977Sci...198.1056I}}&amp;lt;/ref&amp;gt; Keyin David Goeddel va Dennis Kleid guruhga qoʻshildi va 1978-yilda sintetik inson [[Insulin|insulini]] bilan muvaffaqiyatga hissa qoʻshdi.&lt;br /&gt;
&lt;br /&gt;
1990-yilda [[Roche|F. Hoffmann-La Roche AG]] Genentech kompaniyasining asosiy ulushini sotib oldi.&amp;lt;ref name=&amp;quot;NYTroche&amp;quot;&amp;gt;{{Yangiliklar manbasi |last=Fisher |first=Lawrence M. |date=October 1, 2000 |title=Genentech: Survivor Strutting Its Stuff |work=The New York Times |url=https://www.nytimes.com/2000/10/01/business/genentech-survivor-strutting-its-stuff.html?pagewanted=all&amp;amp;_r=0 |url-status=live |access-date=February 19, 2017 |archive-url=https://web.archive.org/web/20170404185137/http://www.nytimes.com/2000/10/01/business/genentech-survivor-strutting-its-stuff.html?pagewanted=all&amp;amp;_r=0 |archive-date=April 4, 2017}}&amp;lt;/ref&amp;gt; 2006-yilda Genentech oʻzining birinchi sotib olish shartnomasida Tanoxni sotib oldi. Tanox Xolairni ishlab chiqishni boshlagan va Novartis va Genentech bilan hamkorlikda ishlab chiqish yakunlangan; sotib olish Genentechga koʻproq daromadni saqlab qolish imkonini berdi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |date=November 9, 2006 |title=Genentech strikes $919M deal to buy Tanox |work=FierceBiotech |url=http://www.fiercebiotech.com/biotech/genentech-strikes-919m-deal-to-buy-tanox |url-status=live |archive-url=https://web.archive.org/web/20170404155601/http://www.fiercebiotech.com/biotech/genentech-strikes-919m-deal-to-buy-tanox |archive-date=April 4, 2017}}&amp;lt;/ref&amp;gt; 2009-yil mart oyida Roche Genentech kompaniyasini oʻzi nazorat qilmagan aksiyalarni taxminan 46,8 milliard dollarga sotib oldi.&amp;lt;ref name=&amp;quot;Morse_WSJ2006&amp;quot;&amp;gt;{{Yangiliklar manbasi |last=Morse |first=Andrew |date=May 10, 2006 |title=Chugai Shares Post Healthy Gain On Prospects for Cancer Drug |work=The Wall Street Journal |url=https://www.wsj.com/articles/SB114720225204948046?mod=googlenews_wsj |access-date=September 26, 2008}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;Staff_GEN2008&amp;quot;&amp;gt;{{Yangiliklar manbasi |last=Staff writers |date=July 21, 2008 |title=Roche Makes $43.7B Bid for Genentech |work=[[Gen. Eng. Biotechnol. News|Genetic Engineering &amp;amp; Biotechnology News]] |url=http://www.genengnews.com/news/bnitem.aspx?name=39080941 |url-status=live |access-date=September 26, 2008 |archive-url=https://web.archive.org/web/20090203010727/http://www.genengnews.com/news/bnitem.aspx?name=39080941 |archive-date=February 3, 2009 |issn=1935-472X}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Pollack |first=Andrew |date=March 12, 2009 |title=Roche Agrees to Buy Genentech for $46.8 Billion |language=en-US |work=The New York Times |url=https://www.nytimes.com/2009/03/13/business/worldbusiness/13drugs.html |access-date=April 3, 2020 |issn=0362-4331}}&amp;lt;/ref&amp;gt; 2014-yil iyul oyida Genentech/Roche Seragonni kichik molekulali saraton dori-darmonlari nomzodlari uchun 725 million dollar naqd pulga sotib oldi, qoʻshimcha 1 milliard dollarlik toʻlovlar Seragon qatoridagi mahsulotlarning muvaffaqiyatli rivojlanishiga bogʻliq.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Staff writers |date=July 2, 2014 |title=Genentech acquires Seragon |work=[[Gen. Eng. Biotechnol. News|Genetic Engineering &amp;amp; Biotechnology News]] |url=http://www.genengnews.com/gen-news-highlights/genentech-acquires-seragon-for-up-to-1-725b/81250056 |url-status=live |access-date=July 2, 2014 |archive-url=https://web.archive.org/web/20140714133409/http://www.genengnews.com/gen-news-highlights/genentech-acquires-seragon-for-up-to-1-725b/81250056/ |archive-date=July 14, 2014}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Tadqiqot ==&lt;br /&gt;
Genentech tadqiqotga asoslangan kashshof [[biotexnologiya]] kompaniyasi&amp;lt;ref name=&amp;quot;NYTroche&amp;quot;/&amp;gt; boʻlib, u ichki va hamkorlik orqali ilmiy-tadqiqot ishlarini olib borishda davom etmoqda.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |date=July 3, 2012 |title=Three Years After Merger, Genentech R&amp;amp;D Outshines That of Roche&amp;#039;s {{!}} GEN News Highlights |work=Genetic Engineering News |url=http://www.genengnews.com/gen-news-highlights/three-years-after-merger-genentech-r-amp-d-outshines-that-of-roche/81246997/?kwrd=Dalcetrapib |url-status=live |access-date=September 18, 2016 |archive-url=https://web.archive.org/web/20170405023846/http://www.genengnews.com/gen-news-highlights/three-years-after-merger-genentech-r-amp-d-outshines-that-of-roche/81246997?kwrd=Dalcetrapib |archive-date=April 5, 2017}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{Veb manbasi|sarlavha=Living 10 Years in the Future|url=http://www.gene.com/scientists|nashriyot=Genentech|arxivurl=https://web.archive.org/web/20160801073259/http://www.gene.com/scientists|arxivsana=August 1, 2016}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Genentech tadqiqot hamkorliklari quyidagilarni oʻz ichiga oladi:&lt;br /&gt;
&lt;br /&gt;
* 2008-yilda Genentech obinutuzumabni ishlab chiqish uchun Roche va uning shoʻba korxonasi GlycArt bilan hamkorlik qildi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Carroll |first=John |date=October 3, 2008 |title=Genentech teams with Glycart on antibody program |work=FierceBiotech |url=http://www.fiercebiotech.com/biotech/genentech-teams-glycart-on-antibody-program |url-status=live |access-date=September 18, 2016 |archive-url=https://web.archive.org/web/20170404155446/http://www.fiercebiotech.com/biotech/genentech-teams-glycart-on-antibody-program |archive-date=April 4, 2017}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
* 2010-yil fevral oyida Genentech San-Fransiskodagi Kaliforniya universiteti bilan hamkorlikka kirishdi, ular bilan oʻn beshga yaqin boshqa hamkorlikda ishladilar, bu safar nevrologiyada kichik molekula dori kashfiyoti boʻyicha hamkorlik qildi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |date=February 19, 2010 |title=UCSF enters drug discovery agreement with Genentech |work=FierceBiotech |url=http://www.fiercebiotech.com/biotech/ucsf-enters-drug-discovery-agreement-genentech |url-status=live |access-date=September 18, 2016 |archive-url=https://web.archive.org/web/20170404155549/http://www.fiercebiotech.com/biotech/ucsf-enters-drug-discovery-agreement-genentech |archive-date=April 4, 2017}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
* 2014-yil oktyabr oyida Genentech Ayova shtatida joylashgan NewLink Genetics bilan nazorat nuqtasi ingibitorlari boʻyicha hamkorlik qilish uchun 150 million dollar oldindan toʻladi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Carroll |first=John |date=October 20, 2014 |title=Genentech pays 2350M upfront to partner on NewLink&amp;#039;s immuno-oncology drug |work=FierceBiotech |url=http://www.fiercebiotech.com/partnering/genentech-pays-150m-upfront-to-partner-on-newlink-s-immuno-oncology-drug |url-status=live |access-date=September 18, 2016 |archive-url=https://web.archive.org/web/20160614043146/http://www.fiercebiotech.com/partnering/genentech-pays-150m-upfront-to-partner-on-newlink-s-immuno-oncology-drug |archive-date=June 14, 2016}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
* 2015-yil iyun oyida u kompaniyada maʼlumotlar boʻyicha olimlarning keyingi avlodini tayyorlash va yollashda yordam berish uchun The Data Incubator bilan keng koʻlamli hamkorlikka kirdi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |title=The Promise and Challenge of Big Data for Pharma |url=https://hbr.org/2016/11/the-promise-and-challenge-of-big-data-for-pharma |url-status=live |access-date=April 5, 2017 |archive-url=https://web.archive.org/web/20170405171004/https://hbr.org/2016/11/the-promise-and-challenge-of-big-data-for-pharma |archive-date=April 5, 2017}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
* 2015-yil yanvar oyida u 23andMe bilan 60 million dollarlik shartnoma imzoladi, bu Genentechga 23andMe tomonidan ushlab turilgan genomik va bemor tomonidan xabar qilingan maʼlumotlarga kirish imkonini berdi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Herper |first=Matthew |title=Surprise! With $60 Million Genentech Deal, 23andMe Has A Business Plan |work=Forbes |url=https://www.forbes.com/sites/matthewherper/2015/01/06/surprise-with-60-million-genentech-deal-23andme-has-a-business-plan/#28855bf37927 |url-status=live |access-date=August 16, 2017 |archive-url=https://web.archive.org/web/20170816224058/https://www.forbes.com/sites/matthewherper/2015/01/06/surprise-with-60-million-genentech-deal-23andme-has-a-business-plan/#28855bf37927 |archive-date=August 16, 2017}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
* 2015-yil oktabr oyida u Nimbus Therapeutics bilan kremniyli dori vositalarini kashf qilish platformasida Nimbus’dan yetakchilarni ishlab chiqish uchun hamkorlikni boshladi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Garde |first=Damian |date=October 20, 2015 |title=Genentech co-signs Nimbus&amp;#039; computer-aided R&amp;amp;D with an oncology pact |work=FierceBiotech |url=http://www.fiercebiotech.com/partnering/genentech-co-signs-nimbus-computer-aided-r-d-an-oncology-pact |url-status=live |access-date=September 18, 2016 |archive-url=https://web.archive.org/web/20160711042119/http://www.fiercebiotech.com/partnering/genentech-co-signs-nimbus-computer-aided-r-d-an-oncology-pact |archive-date=July 11, 2016}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
* 2016-yil iyun oyida Genentech Epizymening EZH2 ingibitori tazemetostat Genentechning atezolizumab bilan sinergik boʻlishini oʻrganish uchun klinik sinovlarni oʻtkazish uchun Epizyme bilan hamkorlik qildi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Lawrence |first=Stacy |date=June 23, 2016 |title=Epizyme nabs combo trial deal with Genentech for NHL candidate {{!}} FierceBiotech |work=www.fiercebiotech.com |url=http://www.fiercebiotech.com/biotech/epizyme-nabs-combo-trial-deal-genentech-for-nhl-candidate |url-status=live |access-date=September 18, 2016 |archive-url=https://web.archive.org/web/20160906121630/http://www.fiercebiotech.com/biotech/epizyme-nabs-combo-trial-deal-genentech-for-nhl-candidate |archive-date=September 6, 2016}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
* 2016-yil avgust oyida kompaniya Carmot Therapeutics bilan hamkorlikni boshladi, unda Carmot yangi nomzodlarni topadi va Genentech ularni ishlab chiqadi.&amp;lt;ref&amp;gt;{{Cite journal|last=&amp;lt;!--journal staff--&amp;gt;|date=August 2016|title=Carmot to Use Lead-Identification Technology in Collab with Genentech|journal=[[Gen. Eng. Biotechnol. News|Genetic Engineering &amp;amp; Biotechnology News]]|volume=36|issue=14|page=17}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
* 2016-yil sentyabr oyida Genentech Isroilning BioLineRx kompaniyasi bilan Genentech oʻzining atezolizumab bilan birlashtirishni maqsad qilgan nazorat nuqtasi inhibitori boʻyicha hamkorlik qildi.&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |last=Lawrence |first=Stacy |date=September 7, 2016 |title=Genentech, BioLineRx pair up a checkpoint inhibitor combo |work=FierceBiotech |url=http://www.fiercebiotech.com/biotech/genentech-biolinerx-pair-up-a-checkpoint-inhibitor-combo |url-status=live |access-date=September 18, 2016 |archive-url=https://web.archive.org/web/20160911013920/http://www.fiercebiotech.com/biotech/genentech-biolinerx-pair-up-a-checkpoint-inhibitor-combo |archive-date=September 11, 2016}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Imkoniyatlar ==&lt;br /&gt;
[[Fayl:Genentech_Building_31.jpg|link=//upload.wikimedia.org/wikipedia/commons/thumb/a/ac/Genentech_Building_31.jpg/220px-Genentech_Building_31.jpg|right|thumb| 31-bino, Genentech bosh qarorgohidagi yangi binolardan biri]]&lt;br /&gt;
Genentech korporativ shtab-kvartirasi Janubiy San-Fransiskoda, Kaliforniyada joylashgan ({{Coord|37.657|-122.379|name=Genentech}}), Kaliforniya shtati Vakavil, [[Oceanside (California)|Oceanside, Kaliforniya]] va [[Hillsboro (Oregon)|Hillsboro, Oregon]]&amp;lt;nowiki/&amp;gt;da qoʻshimcha ishlab chiqarish quvvatlari ham bor.&lt;br /&gt;
&lt;br /&gt;
2006-yil dekabr oyida Genentech oʻzining [[Porriño]] ([[Ispaniya]]) zavodini Lonzaga sotdi va Lonzaning [[Singapur|Singapurda]] qurilayotgan sut emizuvchilar hujayra madaniyatini ishlab chiqarish zavodini sotib olish uchun eksklyuziv huquqni qoʻlga kiritdi. 2007-yil iyun oyida Genentech butun dunyo boʻylab Lucentis (ranibizumab inyeksiyasi) dori moddasini ommaviy ishlab chiqarish uchun Singapurda &amp;#039;&amp;#039;E. coli&amp;#039;&amp;#039; ishlab chiqarish zavodini qurish va rivojlantirishni boshladi. &lt;br /&gt;
&lt;br /&gt;
== Mahsulotlar xronologiyasi ==&lt;br /&gt;
&lt;br /&gt;
* 1982: AQSh oziq-ovqat va farmatsevtika idorasi (FDA) tomonidan tasdiqlangan sintetik „inson“ [[insulin]] insulin ishlab chiqaruvchisi Eli Lilly and Company bilan hamkorlikda, FDA tasdiqlash jarayoni orqali mahsulotni ishlab chiqargan. Mahsulot ([[Insulin terapiyasi|Humulin]]) Lilly tomonidan litsenziyalangan va ishlab chiqarilgan va birinchi marta tasdiqlangan genetik muhandislik inson terapevti edi.&lt;br /&gt;
* 1985: Protropin (somatrem): oʻsish gormoni yetishmovchiligi boʻlgan bolalar uchun qoʻshimcha oʻsish gormoni (ishlab chiqarish toʻxtatilgan, 2004).&lt;br /&gt;
* 1987: Aktivaza (alteplaz): Oʻtkir [[miokard infarkti]] boʻlgan bemorlarda qon quyqalarini eritish uchun ishlatiladigan rekombinant toʻqima plazminogen faollashtiruvchisi (tPa). Gemorragik boʻlmagan insultni davolash uchun ham qoʻllanadi.&lt;br /&gt;
* 1990: Actimmune ([[Interferon|interferon gamma 1b]]): Surunkali granulomatoz kasallikni davolash (Intermune litsenziyasi).&lt;br /&gt;
* 1993: Nutropin (rekombinant somatropin): Surunkali buyrak kasalligi tufayli buyrak transplantatsiyasidan oldin davolash uchun bolalar va kattalar uchun oʻsish gormoni .&lt;br /&gt;
* 1993: Pulmozim (dornaza alfa): [[Mukovitsidoz|Kistik]] fibrozli bolalar va yoshlar uchun inhalatsiyani davolash — rekombinant DNK.&lt;br /&gt;
* 1997: Rituxan (rituximab): Hodgkin boʻlmagan limfomalarning oʻziga xos turlarini davolash. 2006-yilda revmatoid artrit uchun ham tasdiqlangan.&lt;br /&gt;
* 1998: Gerceptin (trastuzumab): HER2 genini haddan tashqari koʻrsatadigan oʻsmalari boʻlgan metastatik koʻkrak saratoni bemorlarini davolash. Yaqinda koʻkrak bezi saratoni uchun yordamchi terapiya uchun tasdiqlangan. FDA ham yaqinda HER2 retseptorlari joyi ijobiy boʻlgan metastatik oshqozon saratoni uchun Trastuzumabni tasdiqladi.&lt;br /&gt;
* 2000: TNKase (tenekteplaza): oʻtkir [[Miokard infarkti|miyokard infarktini]] davolash uchun preparat.&lt;br /&gt;
* 2003: Xolair (omalizumab): oʻrtacha va ogʻir surunkali [[Bronxial astma|astma]] uchun teri ostiga inyeksiya.&lt;br /&gt;
* 2003: Raptiva (efalizumab): [[psoriaz]] rivojlanishiga olib keladigan T hujayralarining faollashishi va qayta faollashishini blokirovka qilish uchun moʻljallangan antitana. [http://www.xoma.com XOMA] bilan hamkorlikda ishlab chiqilgan. 2009-yilda progressiv multifokal leykoensefalopatiya haqidagi xabarlardan soʻng AQSh bozori ixtiyoriy ravishda olib tashlandi.&lt;br /&gt;
* 2004: Avastin (bevacizumab): [[Yoʻgʻon ichak|Yoʻgʻon ichak yoki toʻgʻri ichakning]] [[Toʻgʻri ichak|metastatik]] saratonini davolash uchun anti-VEGF monoklonal antitanasi. 2006-yilda Mahalliy darajada rivojlangan, takroriy yoki metastatik kichik hujayrali boʻlmagan oʻpka saratoni uchun ham tasdiqlangan. 2008-yilda ilgari davolanmagan HER2-salbiy koʻkrak saratoni uchun kimyoterapiya bilan birgalikda Avastinga tezlashtirilgan ruxsat berildi. 2009-yilda Avastin glioblastoma multiformeni davolash uchun beshinchi, metastatik buyrak hujayrali karsinomasini davolash uchun oltinchi ruxsatnomani oldi. U koʻkrak bezi saratonini ilgʻor davolashda maʼqullangani uchun eng koʻp eʼlon qilindi, ammo koʻkrak bezi saratonini davolash uchun FDA maʼqullashi keyinchalik 2011-yil noyabr oyida bekor qilindi.&lt;br /&gt;
* 2004: Tarceva (erlotinib): Mahalliy rivojlangan yoki metastatik kichik hujayrali boʻlmagan oʻpka saratoni va oshqozon osti bezi saratoni bilan ogʻrigan bemorlarni davolash.&lt;br /&gt;
* 2006: Lucentis (ranibizumab inyeksiyasi): neovaskulyar (hoʻl) yoshga bogʻliq makula naslini (AMD) davolash. FDA LUCENTISni ustuvor koʻrib chiqishdan soʻng (olti oy) tasdiqladi. Genentech mahsulotni joʻnatishni 2006-yil 30-iyunda, mahsulot tasdiqlangan kunidan boshladi.&lt;br /&gt;
* 2010: Actemra (tocilizumab): Birinchi interleykin-6 (IL-6) retseptorlarini ingibitorlik qiluvchi monoklonal antitana revmatoid artritni (RA) davolash uchun tasdiqlangan.&lt;br /&gt;
* 2011: Zelboraf (vemurafenib): BRAF mutatsiyasidan kelib chiqqan [[Melanoma|metastatik melanomani]] davolash uchun.&lt;br /&gt;
* 2012: Erivedge (vismodegib): rivojlangan [[Bazalioma|bazal hujayrali karsinomani]] (BCC) davolash.&lt;br /&gt;
* 2012: Perjeta (pertuzumab): ilgari davolanmagan HER2-musbat metastatik koʻkrak saratoni bilan ogʻrigan bemorlarni davolash uchun Herceptin (trastuzumab) va dosetaksel kimyoterapiyasi bilan birgalikda foydalanish uchun.&lt;br /&gt;
* 2013: Kadcyla (ado-trastuzumab emtansine): FDA maʼqullagan birinchi Genentech antitana-dori konjugati (ADC). U HER2-musbat metastatik koʻkrak saratonini davolashda ishlatiladigan sitotoksik vosita mertansin (DM1) bilan bogʻlangan trastuzumabdan (Gerceptin) iborat.&lt;br /&gt;
* 2013: Gazyva (obinutuzumab): ilgari davolanmagan surunkali limfotsitik leykemiya (CLL) bilan ogʻrigan bemorlarni davolash uchun xlorambusil bilan birgalikda foydalanish uchun. Gazyva FDA maʼqullashini olgan birinchi doridir.&lt;br /&gt;
* 2014: Esbriet (pirfenidon): Idiopatik oʻpka fibrozini (IPF) davolash uchun anti-fibrotik dori. Intermune, Inc tomonidan ishlab chiqilgan.&lt;br /&gt;
* 2015: Kotellik (kobimetinib): BRAF mutatsiyasidan kelib chiqqan [[Melanoma|metastatik melanomani]] davolash uchun ZELBORAF (vemurafenib) bilan birgalikda foydalanish uchun.&lt;br /&gt;
* 2015: Alesensa (alektinib): Kichik hujayrali boʻlmagan oʻpka saratoni (NSCLC) uchun davolash.&lt;br /&gt;
* 2016: Venclexta (venetoclax): Surunkali limfotsitik leykemiya (CLL) bilan ogʻrigan, 17p deletsiya deb ataladigan xromosoma anormalligi boʻlgan va kamida bitta oldingi terapiya bilan davolangan bemorlarni davolash.&lt;br /&gt;
* 2016: Tecentriq (atezolizumab): Platinaga asoslangan kimyoterapiya muvaffaqiyatsizlikka uchragan qovuq saratoni yoki metastatik kichik hujayrali boʻlmagan oʻpka saratoni (NSCLC) ni davolash uchun birinchi sinfdagi PD-L1 antitanasi. Tecentriqga II fazaning istiqbolli natijalari tufayli qovuq saratonining ilgʻor koʻrsatkichi uchun tezlashtirilgan ruxsat berildi.&lt;br /&gt;
* 2017: Ocrevus (okrelizumab): FDA tomonidan tasdiqlangan birinchi terapiya, ham relapsing-remitting multipl skleroz (RRMS) va birlamchi progressiv multipl skleroz (PPMS) davolaydi. Kasallikning PPMS shakli ilgari tasdiqlangan davolash usullariga ega emas edi.&lt;br /&gt;
* 2017: Hemlibra (emicizumab): gemofiliyani davolash A. Chugai Pharmaceutical Co. tomonidan ishlab chiqilgan.&lt;br /&gt;
* 2018: Xofluza (Baloxavir marboxil): A grippi va B grippini davolash uchun antiviral dori. Shionogi tomonidan ishlab chiqilgan.&lt;br /&gt;
* 2019: Polivy (Polatuzumab vedotin-piiq): Bendamustin va rituximab bilan birgalikda ishlatilganda diffuz yirik B hujayrali limfomani davolash.&lt;br /&gt;
&lt;br /&gt;
== Mukofotlar va eʼtiroflar ==&lt;br /&gt;
&lt;br /&gt;
* &amp;#039;&amp;#039;Fortune jurnali&amp;#039;&amp;#039; Genentechni 22 yil davomida „Ishlash uchun eng yaxshi 100 ta kompaniya“ roʻyxatiga kiritdi va 2006-yildagi roʻyxatida birinchi oʻrinni egalladi. Yillar davomida reyting 1-raqamdan 80-raqamgacha oʻzgarib turadi&amp;lt;ref&amp;gt;{{Veb manbasi|url=https://fortune.com/best-companies/2020/genentech/|sarlavha=Genentech|ish=Fortune|til=en-US|kirish sanasi=March 24, 2020|qaralgan sana=2022-09-29|arxivsana=2021-04-10|arxivurl=https://web.archive.org/web/20210410104624/https://fortune.com/best-companies/2020/genentech/}}&amp;lt;/ref&amp;gt;. Reyting xodimlarning anonim so‘rovnomaga bergan javoblari hamda kompaniya siyosati va madaniyatini baholashga asoslanadi.&lt;br /&gt;
* Genentech 2004, 2006-8 va 2010-11 yillarda &amp;#039;&amp;#039;Working Mother jurnali&amp;#039;&amp;#039; tomonidan ishlaydigan onalar uchun 100 ta eng yaxshi kompaniyalardan biri deb topildi&amp;lt;ref&amp;gt;{{Veb manbasi|url=http://www.workingmother.com/?service=vpage/106l|sarlavha=Working Mother Magazine|kirish sanasi=February 20, 2020|arxivurl=https://web.archive.org/web/20110404034540/http://www.workingmother.com/?service=vpage%2F106L|arxivsana=April 4, 2011}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
* U &amp;#039;&amp;#039;Business Ethics Magazine&amp;#039;&amp;#039; tomonidan 2006-yilda 100 ta eng yaxshi korporativ fuqarolardan biri sifatida tan olingan. Kompaniya TechNet&amp;lt;ref&amp;gt;{{Veb manbasi|url=http://www.technet.org/members/by_name/?alphaSect=L|sarlavha=TechNet|kirish sanasi=May 17, 2008|arxivurl=https://web.archive.org/web/20090203171941/http://www.technet.org/members/by_name/?alphaSect=L|arxivsana=February 3, 2009}}&amp;lt;/ref&amp;gt; kabi turli siyosat va fuqarolik yetakchilik guruhlarida ishtirok etadi va &amp;#039;&amp;#039;Nature&amp;#039;&amp;#039; jurnali kabi mustaqil uchinchi tomon tadqiqot va nashrlariga homiylik qiladi&amp;lt;ref&amp;gt;{{Veb manbasi|url=http://www.nature.com/nature/supplements/insights/angiogenesis/sponsors.html|sarlavha=Nature|kirish sanasi=May 17, 2008|arxivurl=https://web.archive.org/web/20090203040307/http://www.nature.com/nature/supplements/insights/angiogenesis/sponsors.html|arxivsana=February 3, 2009}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
* Genentech 2010-yil 7-oktabrda &amp;#039;&amp;#039;Science jurnali&amp;#039;&amp;#039; tomonidan eng yaxshi ish beruvchi deb topildi va u yerda toʻqqiz yil ketma-ket shu mukofotni oldi&amp;lt;ref&amp;gt;{{Veb manbasi|url=http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articles/2010_10_08/science.opms.r1000096|sarlavha=Science Magazine|sana=October 8, 2010|kirish sanasi=February 15, 2011|arxivurl=https://web.archive.org/web/20110210191708/http://sciencecareers.sciencemag.org//career_magazine/previous_issues/articles/2010_10_08/science.opms.r1000096|arxivsana=February 10, 2011}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
* 2008-yil mart oyida Genentech ketma-ket ikkinchi yil Fortune tomonidan eng hayratlanarli farmatsevtika kompaniyasi deb topildi.&lt;br /&gt;
* 2010-yil iyul oyida Genentech &amp;#039;&amp;#039;ComputerWorld&amp;#039;&amp;#039; jurnali tomonidan „IT sohasida ishlash uchun eng yaxshi 100 ta joy“ roʻyxatiga kiritildi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |title=No. 58: Genentech, Inc. |work=ComputerWorld Magazine |url=http://www.computerworld.com/action/article.do?command=viewArticleBasic&amp;amp;articleId=318980l |archive-url=https://web.archive.org/web/20090116092611/http://www.computerworld.com/action/article.do?command=viewArticleBasic&amp;amp;articleId=318980l |archive-date=January 16, 2009}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
* 2008-yil dekabr oyida Glassdoor.com Genentech bosh direktori Artur D. Levinsonni 93 % maʼqullash reytingi bilan 2008-yilning „eng yaxshi“ bosh direktori deb baholadi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |date=December 26, 2008 |title=Glassdoor.com Lists Naughtiest and Nicest C.E.O.&amp;#039;s of 2008 |work=The New York Times |url=http://bits.blogs.nytimes.com/2008/12/26/which-ceos-were-naughty-and-nice-in-2008 |url-status=live |access-date=May 3, 2010 |archive-url=https://web.archive.org/web/20111004200638/http://bits.blogs.nytimes.com/2008/12/26/which-ceos-were-naughty-and-nice-in-2008/ |archive-date=October 4, 2011}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
* Genentech 2011-yilda premerasi boʻlgan „Something Ventured“ hujjatli filmida tasvirlangan.&lt;br /&gt;
* &amp;#039;&amp;#039;The Economist&amp;#039;&amp;#039; Genentechni 2013-yilning eng innovatsion korporatsiyasi deb baholadi&amp;lt;ref&amp;gt;{{Yangiliklar manbasi |date=November 30, 2013 |title=Innovation Awards: And the winners are... |work=The Economist |url=https://www.economist.com/news/technology-quarterly/21590752-innovation-awards-our-annual-prizes-recognise-successful-innovators-eight |url-status=live |access-date=August 28, 2017 |archive-url=https://web.archive.org/web/20171107020834/https://www.economist.com/news/technology-quarterly/21590752-innovation-awards-our-annual-prizes-recognise-successful-innovators-eight |archive-date=November 7, 2017}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Manbalar ==&lt;br /&gt;
&amp;lt;references group=&amp;quot;&amp;quot; responsive=&amp;quot;0&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/references&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Qoʻshimcha maʼlumot ==&lt;br /&gt;
&lt;br /&gt;
* Salli Smit Xyuz. &amp;#039;&amp;#039;Genentech: Biotexnologiyaning boshlanishi&amp;#039;&amp;#039; (Chikago universiteti universiteti; 2011-yil).&lt;br /&gt;
* GenenLab noutbuki: [http://blog.zymergi.com/2013/01/origins-biotech-genentech.html „Biotexnikaning boshlanishi“] — Genentech xodimlari uchun yangi kitobcha (1996)&lt;br /&gt;
* &amp;#039;&amp;#039;Daromad uchun retsept: Farmatsevtika sanoati fan va biznes oʻrtasidagi nopok nikohni qanday qilib bankrot qildi,&amp;#039;&amp;#039; Linda Marsa, Skribner (1997)&lt;/div&gt;</summary>
		<author><name>Programmer</name></author>
	</entry>
</feed>